Clinical outcomes
In this meta-analysis, we found no difference between nitazoxanide and
placebo in the frequency of positive RTP-PCR results (RR = 0.83; 95% CI
0.58 to 1.17) (Figure 1A) and there was no decreased risk for composite
measure of disease progression (severe COVID-19, ICU admission or
invasive mechanical ventilation) (RR = 0.40; 95% CI 0.08 to 2.13)
(Figure 1B) and deaths (RR = 0.55; 95% CI 0.18 to 1.68) (Figure 1C)
among patients with COVID-19 receiving nitazoxanide. No difference was
shown between groups regarding the frequency of individuals with any
adverse events (RR = 0.83; 95% CI 0.64 to 1.08) (Figure 2).